Teladoc, Inc. (NYSE:TDOC)‘s stock had its “buy” rating reiterated by equities research analysts at KeyCorp in a note issued to investors on Sunday. They currently have a $37.00 price target on the health services provider’s stock. KeyCorp’s target price points to a potential upside of 10.45% from the company’s previous close.

A number of other brokerages have also weighed in on TDOC. William Blair restated an “outperform” rating on shares of Teladoc in a research note on Tuesday, June 20th. Canaccord Genuity reaffirmed a “buy” rating and set a $42.00 target price (up previously from $34.00) on shares of Teladoc in a report on Tuesday, June 20th. Chardan Capital increased their target price on Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, June 20th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $27.00 target price on shares of Teladoc in a report on Monday, June 19th. Finally, Zacks Investment Research downgraded Teladoc from a “hold” rating to a “sell” rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $35.82.

Shares of Teladoc (NYSE TDOC) opened at 33.50 on Friday. The firm has a 50-day moving average price of $34.82 and a 200-day moving average price of $33.03. The stock’s market cap is $1.90 billion. Teladoc has a 52 week low of $14.00 and a 52 week high of $37.55.

Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The business had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter last year, the business earned ($0.38) EPS. Teladoc’s revenue for the quarter was up 68.3% compared to the same quarter last year. On average, analysts forecast that Teladoc will post ($1.44) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Teladoc, Inc. (TDOC) Rating Reiterated by KeyCorp” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/19/teladoc-inc-tdoc-rating-reiterated-by-keycorp.html.

In related news, insider Adam C. Vandervoort sold 53,806 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.92, for a total value of $1,663,681.52. Following the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.47% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. lifted its holdings in shares of Teladoc by 125.7% in the 1st quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock worth $3,288,000 after purchasing an additional 73,231 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in shares of Teladoc in the 1st quarter worth approximately $6,411,000. Blair William & Co. IL bought a new stake in shares of Teladoc in the 1st quarter worth approximately $218,000. Swiss National Bank lifted its holdings in shares of Teladoc by 37.5% in the 1st quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock worth $1,420,000 after purchasing an additional 15,500 shares during the last quarter. Finally, Riverbridge Partners LLC bought a new stake in shares of Teladoc in the 2nd quarter worth approximately $23,392,000.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.